Enclomiphene is a non-steroidal estrogen receptor antagonist and the trans isomer of clomiphene citrate, originally developed for the treatment of ovarian dysfunction in women. Researchers primarily study enclomiphene for its potential role in managing secondary male hypogonadism, particularly in men who wish to preserve fertility. Key findings from recent studies indicate that enclomiphene can significantly increase serum testosterone levels by elevating luteinizing hormone and follicle-stimulating hormone levels, while maintaining normal sperm counts, in contrast to traditional testosterone replacement therapies. Current research continues to explore the efficacy and safety of enclomiphene in various populations, with promising results supporting its use as an alternative to testosterone gel therapy.